Eupraxia Pharmaceuticals Inc. Share Price & Technical Analysis
EPRX · $7.53 (+6.06%)
Healthcare / Biotechnology
$7.53
+6.06%
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee oste…
Price chart
Seasonality
May has 0 positive and 2 negative years (last 3 years shown)
-9% return in May, -1% avg return in past 3 year May month.
0% return in 2026, 55% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 9% | 4% | -11% | 7% | -9% | – | – | – | – | – | – | – | 0% |
| 25 | -6% | 37% | -17% | 32% | -2% | 49% | -13% | 4% | 9% | -7% | 9% | 21% | 114% |
| 24 | – | – | – | -23% | 0% | -4% | 17% | -11% | -4% | -4% | 27% | -3% | -4% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Uptrend · Uptrend
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$458.81M
P/E ratio
—
52W high
$9.32
52W low
$3.82
Volume
3,55,640
Beta
1.42
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Eupraxia Pharmaceuticals Inc. share price today?
- Eupraxia Pharmaceuticals Inc. (EPRX) last traded around $7.53 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does EPRX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for EPRX. Download the app for real-time alerts.
- How can I analyze Eupraxia Pharmaceuticals Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.